406 related articles for article (PubMed ID: 29233541)
1. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
Vancurova I; Uddin MM; Zou Y; Vancura A
Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Slingerland M; Guchelaar HJ; Gelderblom H
Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
5. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.
Qiu T; Zhou L; Zhu W; Wang T; Wang J; Shu Y; Liu P
Future Oncol; 2013 Feb; 9(2):255-69. PubMed ID: 23414475
[TBL] [Abstract][Full Text] [Related]
6. IKK inhibition increases bortezomib effectiveness in ovarian cancer.
Singha B; Gatla HR; Phyo S; Patel A; Chen ZS; Vancurova I
Oncotarget; 2015 Sep; 6(28):26347-58. PubMed ID: 26267322
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors.
Zhou N; Xu W; Zhang Y
Drug Discov Ther; 2015 Jun; 9(3):147-55. PubMed ID: 26193935
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors: a patent review (2009 - 2011).
Carafa V; Miceli M; Altucci L; Nebbioso A
Expert Opin Ther Pat; 2013 Jan; 23(1):1-17. PubMed ID: 23094822
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Mottamal M; Zheng S; Huang TL; Wang G
Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
[TBL] [Abstract][Full Text] [Related]
14. Drug Combinations with HDAC Inhibitors in Antitumor Therapy.
Arrighetti N; Corno C; Gatti L
Crit Rev Oncog; 2015; 20(1-2):83-117. PubMed ID: 25746106
[TBL] [Abstract][Full Text] [Related]
15. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
16. Multi-targeted histone deacetylase inhibitors in cancer therapy.
Ai T; Cui H; Chen L
Curr Med Chem; 2012; 19(4):475-87. PubMed ID: 22204328
[TBL] [Abstract][Full Text] [Related]
17. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
18. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
20. Natural products as zinc-dependent histone deacetylase inhibitors.
Tan S; Liu ZP
ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
